Home/Pipeline/OPC1

OPC1

Acute Spinal Cord Injury

Phase 1/2aActive

Key Facts

Indication

Acute Spinal Cord Injury

Phase

Phase 1/2a

Status

Active

Company

Lineage Cell Therapeutics

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.

View full company profile

Therapeutic Areas

Neurology Ophthalmology Oncology

Other Acute Spinal Cord Injury Drugs

Drug	Company	Phase	Status
AMFX-200S	Amphix Bio	Preclinical	Active
KP-100IT (HGF protein)	Kringle Pharma	Phase 3	Completed Phase III single-arm study; additional study plan in progress
ExoPTEN	NurExone Biologic	Preclinical	Active
ES135	Eusol Biotech	Phase 3	Active